Clinical Trials

  • Principal Investigator

    Jon T. Giles, MD
    If you currently live in the same household as someone who has tested positive for novel coronavirus (COVID-19), you might be eligible to participate in a trial that will test if a medicine used to prevent malaria, hydroxychloroquine, might reduce the risk of your developing COVID-19 symptoms. COVID-19 is a massive threat to public health worldwide.
  • Principal Investigator

    Elana J. Bernstein, MD, MSc
    The purpose of this study is to find out whether a drug called iloprost is safe to use in people with systemic sclerosis (SSc) (Raynaud's phenomenon), and whether it may help decrease symptomatic digital ischemic episodes (episodes in the fingers).
  • Principal Investigator

    Anca D. Askanase, MD, MPH
    The purpose of this research study is to determine if chloroquine is effective in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections. The time frame for your involvement in the study is 3 months. During month 0, participants will be screened and randomized (like a flip of a coin) to a 3-month chloroquine versus an identical course of placebo. A placebo is a sugar pill which has no active ingredient. Participants will be followed by the investigator during months 1-3 either through in person visit or through telemedicine.
  • Principal Investigator

    Elana J. Bernstein, MD, MSc
    The purpose of this study is to develop a cohort of patients with early scleroderma and to collect data on clinical outcomes, radiological tests, laboratory tests, and to obtain biological specimens for testing.
  • We are recruiting participants to take part in this study who are adults with a clinical diagnosis of rheumatoid arthritis (RA) and have had an inadequate response to Methotrexate (MTX) or other disease-modifying anti rheumatic drugs (DMARDS). If your disease is not controlled after MTX monotherapy (meaning, using only MTX to treat your RA) for 12 weeks at 15mg weekly, and on a stable dose for the previous 4 weeks, we will ask you to be randomly assigned to receive one of the following two treatment regimens. You will continue to take your MTX while in the study.
  • This research is being done to determine how variations in genes may explain the different risk to develop scleroderma (or CREST) seen in African American patients compared to other populations. People who are African American with scleroderma (or CREST) may join. This research involves a blood draw and physical exams.
  • The study aims to compare the effect two different RA treatments on cardiovascular health in patients who are considering a treatment change. The study is recruiting patients who are only taking methotrexate and are switching treatment due to a lack of improvement. The trial will randomize participants to take a TNF inhibitor (Enbrel or Humira) in addition to their methotrexate or to take Triple Therapy (methotrexate + sulfasalazine + hydroxychloroquine sulfate). The study will provide you with all trial medications (excluding methotrexate) for the 6-month duration of the study.